Kimberly Serine, PA
Physician Assistant · Pittston, PANPI 1326473596
Payments from drug & device makers
Across 772 payments — averaging $13.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$942
- Dexcom, Inc.$800
- Sanofi-aventis U.S. LLC$770
- Abbott$734
- plus $4K from 31 others
What the payments were for
- Food & beverage$10,417100%
- Education$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 197 | $1,987 |
| Lilly USA, LLC | 90 | $1,061 |
| AstraZeneca(2 entities) | 42 | $942 |
| Dexcom, Inc. | 58 | $800 |
| Sanofi-aventis U.S. LLC | 71 | $770 |
| Abbott | 51 | $734 |
| Boehringer Ingelheim | 43 | $623 |
| Amgen | 41 | $550 |
| Xeris Pharmaceuticals, Inc. | 30 | $440 |
| AbbVie | 24 | $403 |
| Antares Pharma, Inc. | 30 | $388 |
| Cequr Corporation | 3 | $201 |
| Medtronic | 12 | $192 |
| Merck | 12 | $181 |
| Tolmar, Inc. | 7 | $123 |
| Amarin Pharma, Inc. | 7 | $107 |
| Bayer | 6 | $95 |
| IBSA Pharma Inc. | 5 | $89 |
| Novartis | 4 | $66 |
| Zealand Pharma US, Inc. | 4 | $64 |
| Radius Health, Inc. | 4 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| Tandem Diabetes Care, Inc. | 4 | $61 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Corcept Therapeutics | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Insulet Corporation | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Halozyme Inc | 2 | $29 |
| BETA Bionics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- CeQur Simplicity$108
How this compares
$10,418 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 590 | $704,377 |
| MounjaroTirzepatide | 359 | $422,272 |
| JardianceEmpagliflozin | 319 | $297,371 |
| FarxigaDapagliflozin Propanediol | 165 | $154,217 |
| TradjentaLinagliptin | 123 | $108,396 |
| Tresiba Flextouch U-100Insulin Degludec | 165 | $101,795 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 119 | $94,519 |
| Tresiba Flextouch U-200Insulin Degludec | 84 | $86,061 |
| TrulicityDulaglutide | 73 | $78,668 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $60,456 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $57,016 |
| JanuviaSitagliptin Phosphate | 70 | $54,006 |
| Novolog FlexpenInsulin Aspart | 148 | $51,987 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 47 | $50,697 |
| RybelsusSemaglutide | 37 | $48,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog, Fiasp | $1,987 | $835,599739 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,061 | $514,083468 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $623 | $446,657493 claims |
| AstraZenecaFarxiga | $942 | $154,217165 claims |
| MerckJanuvia, Janumet, Janumet Xr | $181 | $78,644103 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $770 | $50,07954 claims |
| AbbVieSynthroid | $403 | $21,922367 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $9,034893 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Pittston
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.